Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18282510 | 0.88 | EPHA2 (0.51) | EPHA2KDREPHB4GPR119ACHE | |
| SCHEMBL386442 | 0.85 | EPHA2 (0.46) | EPHA2KDREPHB4GPR119ACHE | |
| SCHEMBL391002 | 0.84 | EPHA2 (0.47) | EPHA2KDREPHB4GPR119ACHE | |
| SCHEMBL390557 | 0.84 | EPHA2 (0.47) | EPHA2KDREPHB4GPR119ACHE | |
| SCHEMBL14991092 | 0.79 | GPR119 (0.47) | GPR119ACHEPIK3CAADORA2AADORA1 | |
| SCHEMBL388598 | 0.78 | HDAC4 (0.48) | GPR119ACHEPIK3CAADORA2AADORA1 | |
| SCHEMBL16197362 | 0.76 | GPR119 (0.46) | GPR119ACHEPIK3CAADORA2AADORA1 | |
| SCHEMBL28552685 | 0.76 | HDAC4 (0.60) | GPR119ACHEPIK3CAADORA2AADORA1 | |
| SCHEMBL10297496 | 0.75 | GPR119 (0.55) | GPR119ACHEPIK3CAADORA2AADORA1 | |
| SCHEMBL11956922 | 0.73 | GPR119 (0.45) | EPHA2KDREPHB4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | SYMPHONY EVOLUTION, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-1521747-B1 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | SYMPHONY EVOLUTION INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9359332-B2 | Processes for the preparation of substituted quinazolines | SYMPHONY EVOLUTION, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160129032-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-9163006-B2 | — | — | 2015-10-20 | — | — | US | disclosed |
| US-20140155418-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8658654-B2 | Receptor-type kinase modulators and methods of use | SYMPHONY EVOLUTION, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2277867-B1 | Compounds, pharmaceutical compositions thereof and their use in treating cancer | SYMPHONY EVOLUTION INC (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-2280003-A2 | Process for preparing receptor-type kinase modulators | Symphony Evolution, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2277867-A2 | Compounds, pharmaceutical compositions thereof and their use in treating cancer | Symphony Evolution, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-12-24 | — | — | US | disclosed |
| US-7576074-B2 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-08-18 | — | — | US | disclosed |
| EP-1521747-A4 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | disclosed |
| EP-1521747-A2 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004006846-A2 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | EPHA2 2/4885KDR 17/4885EPHB4 16/4885 |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | EGFR, ERBB4, ERBB3 | EPHA2 4/4885KDR 16/4885EPHB4 17/4885 |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | EPHA2 2/4885KDR 17/4885EPHB4 16/4885 |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | EPHA2 2/4885KDR 17/4885EPHB4 16/4885 |
| US-20160129032-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | EPHA2 2/4885KDR 17/4885EPHB4 16/4885 |
| US-20140155418-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | EPHA2 2/4885KDR 17/4885EPHB4 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.